CIR New and Noteworthy
Information about CIR research, vaccines in the news, infectious diseases, and articles featuring CIR staff and faculty.
CIR Research and Articles featuring Faculty & Staff
Learning more about mosquito transmission may help flavivirus vaccine development
An inpatient challenge study being conducted by CIR's team FIRE aims to learn more about how zika is transmitted between them and humans.
Infecting volunteers with dengue virus shows experimental drug’s promise
Study leader Anna Durbin discusses the power and limits of a provocative human challenge trial
Scientists deliberately gave women Zika — here’s why
Findings from a challenge study conducted by CIR's Team FIRE indicate that the two strains of Zika administered in the trial can be safely and effectively used to infect participants in a Zika vaccine trial.
How Human Challenge Trials Accelerate Vaccine Development
Vaccinated, intentionally infected, and sequestered in a hospital unit, volunteers help researchers fast-track promising vaccine candidates.
Vaccines in the News
FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus
The U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.
COVID-19 vaccination campaign saved 2.4 million lives, according to health economists
A working paper by researchers from the University of Southern California and Brown University analyzed the global impacts of COVID-19 vaccines.
Getting a Flu Vaccine and a COVID-19 Vaccine at the Same Time
Coadministration of vaccines refers to giving or getting more than one vaccine during a visit. This is common clinical practice. While there are some exceptions, many vaccines can be given at the same visit.
First RSV Vaccine Approved in the US
The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.